Source: FDA, National Drug Code (US) Revision Year: 2020
WinRho SDF is a sterile, liquid gamma globulin (IgG) fraction containing antibodies to the Rho(D) antigen (D antigen). WinRho SDF is to be administered intravenously for the treatment of ITP and either intravenously or intramuscularly for the suppression of Rh isoimmunization.
WinRho SDF is prepared from human plasma by an anion-exchange column chromatography method. The manufacturing process includes two steps implemented specifically for viral clearance. The solvent detergent treatment step (using tri-n-butyl phosphate and octoxynol) is effective in inactivating lipid enveloped viruses such as hepatitis B, hepatitis C, and HIV. Virus filtration, using a 20N virus filter, is effective in the removal of some non-lipid enveloped viruses. These two processes are designed to increase product safety by reducing the risk of transmission of enveloped and non-enveloped viruses, respectively. In addition to the two specific steps, the anion-exchange chromatography step contributes to the removal of small non-lipid enveloped viruses.
The inactivation and reduction of known enveloped and non-enveloped model viruses were validated in laboratory studies as summarized in Table 6.
Table 6. Virus Reduction Values Obtained Through Validation Studies:
Enveloped | Non-Enveloped | ||||||
Genome | RNA | DNA | RNA | DNA | |||
Virus | HIV-1 | BVDV | PRV | HAV | EMC | MMV | PPV |
Family | retro | flavi | herpes | picorna | parvo | ||
Size (nm) | 80-100 | 50-70 | 120-200 | 25-30 | 30 | 20-25 | 18-24 |
Anion Exchange Chromatography (partitioning) | n.e. | 2.3 | n.e. | 3.4 | n.e. | ||
20N Filtration (size exclusion) | ≥ 4.7 | ≥ 3.5 | ≥ 5.6* | n.e. | 4.8 | n.e. | 4.1 |
Solvent/Detergent (inactivation) | ≥ 4.7 | ≥ 7.3 | ≥ 5.5 | n.e. | |||
Total Reduction (log10) | ≥ 9.4 | ≥ 10.8 | ≥ 11.1 | 2.3 | 4.8 | 3.4 | 4.1 |
* The PRV was retained by the 0.1 µm pre-filter during the virus validation. Since manufacturing employs a 0.1 µm pre-filter before the 20N filter, the claim of ≥5.6 reduction is considered applicable.
Abbreviations:
HIV-1: human immunodeficiency virus-1; relevant virus for human immunodeficiency virus-1 and model for HIV-2.
BVDV: bovine viral diarrhea virus; model virus for hepatitis C virus (HCV) and West Nile virus (WNV)
PRV: pseudorabies virus; model for large enveloped DNA viruses, including herpes
HAV: human hepatitis A virus; relevant virus for HAV and model for small non-enveloped viruses in general
EMC: encephalomyocarditis virus; model for HAV and for small non-enveloped viruses in general
MMV: murine minute virus; model for human parvovirus B19 and for small non-enveloped viruses in general
PPV: porcine parvovirus; model for human parvovirus B19 and for small non-enveloped viruses in general
n.e.: not evaluated
The product potency is expressed in international units (IU) by comparison to the World Health Organization (WHO) standard. In the past, a full dose of Rho(D) Immune Globulin (Human) has traditionally been referred to as a “300 microgram (mcg)” dose. Potency and dosing recommendations are now expressed in IU by comparison to the WHO anti-Rho(D) standard. The conversion of mcg to IU is: 1 mcg = 5 IU. A 1,500 IU (300 mcg) vial contains sufficient anti-Rho(D) to effectively suppress the immunizing potential of approximately 17 mL of Rho(D) (D-positive) RBCs.
The liquid formulation is stabilized with 10% maltose and 0.03% polysorbate 80. There are no preservatives in the formulation. WinRho SDF does not contain mercury. This product contains ≤40 mcg/mL IgA.
Dosage Forms and Strengths |
---|
WinRho SDF, Rho(D) Immune Globulin Intravenous (Human), is available as a ready to use solution for injection available in single dose vials of 600 IU (120 mcg), 1,500 IU (300 mcg), 2,500 IU (500 mcg), 5,000 IU (1,000 mcg) and 15,000 IU (3,000 mcg). |
How Supplied | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
WinRho SDF is available in packages containing:
Distributed by: Saol Therapeutics Inc., Roswell, GA 30076 |
Drug | Countries | |
---|---|---|
WINRHO | Canada, Hong Kong, Tunisia, Turkey, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.